guest ::
| Home > Publications database > Streamlining and Accelerating the Molecular Tumor Board Process at the University Medical Center Hamburg-Eppendorf. > print |
| Home > Publications database > Streamlining and Accelerating the Molecular Tumor Board Process at the University Medical Center Hamburg-Eppendorf. > print |
| 001 | 302117 | ||
| 005 | 20250819095451.0 | ||
| 024 | 7 | _ | |a 10.1007/s11523-025-01160-6 |2 doi |
| 024 | 7 | _ | |a pmid:40526350 |2 pmid |
| 024 | 7 | _ | |a 1776-2596 |2 ISSN |
| 024 | 7 | _ | |a 1776-260X |2 ISSN |
| 037 | _ | _ | |a DKFZ-2025-01249 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Riemann, Layla Tabea |0 0000-0001-5411-7288 |b 0 |
| 245 | _ | _ | |a Streamlining and Accelerating the Molecular Tumor Board Process at the University Medical Center Hamburg-Eppendorf. |
| 260 | _ | _ | |a Paris |c 2025 |b Springer Verlag France S.A.R.L. |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1755590064_6402 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 500 | _ | _ | |a Volume 20, pages 725–735 |
| 520 | _ | _ | |a We developed, introduced, and evaluated Molecular ONcology Optimized CLinical Evaluation (MONOCLE), a secure, open-source web application at the University Medical Center Hamburg-Eppendorf (UKE), to optimize the analysis and discussion of complex cancer cases in molecular tumor boards (MTB).MONOCLE standardizes and harmonizes documentation, while its integrated Knowledge Connector accelerates literature research for personalized treatment.The system was designed by merging the requirements of the German Network for Personalized Medicine (DNPM), the medical staff involved in the MTB process, and the team developing MONOCLE. The usability was evaluated using the System Usability Scale (SUS) and user tasks. Overall process optimization was measured by the number of automated tasks that can be performed.MONOCLE, introduced into clinical practice in June 2024, significantly reduces time for documentation, as three manual steps now run automatically, and transfer of the data to the DNPM is possible. Its usability and SUS showed positive results, ranging between 92.5 and 97.5.As the first open-source and extendable solution for standardized MTB documentation, MONOCLE enables wider adoption by other medical centers. |
| 536 | _ | _ | |a 312 - Funktionelle und strukturelle Genomforschung (POF4-312) |0 G:(DE-HGF)POF4-312 |c POF4-312 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de |
| 700 | 1 | _ | |a Ataian, Maximilian |b 1 |
| 700 | 1 | _ | |a Hähner, Felicia P S |0 0009-0008-0961-3280 |b 2 |
| 700 | 1 | _ | |a Roth, Benjamin |0 P:(DE-He78)535b205a5a11ddcc83a9301bd41a83f1 |b 3 |u dkfz |
| 700 | 1 | _ | |a Knurr, Alexander |0 P:(DE-He78)d86248f91d13930d4a6ee02207362576 |b 4 |u dkfz |
| 700 | 1 | _ | |a Kamitz, Anne |b 5 |
| 700 | 1 | _ | |a Christopeit, Maximilian |0 0000-0003-4627-0412 |b 6 |
| 700 | 1 | _ | |a Bokemeyer, Carsten |0 0000-0001-6071-7810 |b 7 |
| 700 | 1 | _ | |a Ückert, Frank |b 8 |
| 773 | _ | _ | |a 10.1007/s11523-025-01160-6 |0 PERI:(DE-600)2222136-0 |p 725–735 |t Targeted oncology |v 20 |y 2025 |x 1776-2596 |
| 909 | C | O | |p VDB |o oai:inrepo02.dkfz.de:302117 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 3 |6 P:(DE-He78)535b205a5a11ddcc83a9301bd41a83f1 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 4 |6 P:(DE-He78)d86248f91d13930d4a6ee02207362576 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF4-310 |0 G:(DE-HGF)POF4-312 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Funktionelle und strukturelle Genomforschung |x 0 |
| 914 | 1 | _ | |y 2025 |
| 915 | _ | _ | |a DEAL Springer |0 StatID:(DE-HGF)3002 |2 StatID |d 2024-12-27 |w ger |
| 915 | _ | _ | |a DEAL Springer |0 StatID:(DE-HGF)3002 |2 StatID |d 2024-12-27 |w ger |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b TARGET ONCOL : 2022 |d 2024-12-27 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2024-12-27 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2024-12-27 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2024-12-27 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2024-12-27 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2024-12-27 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1190 |2 StatID |b Biological Abstracts |d 2024-12-27 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2024-12-27 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2024-12-27 |
| 915 | _ | _ | |a IF >= 5 |0 StatID:(DE-HGF)9905 |2 StatID |b TARGET ONCOL : 2022 |d 2024-12-27 |
| 920 | 1 | _ | |0 I:(DE-He78)M130-20160331 |k M130 |l Clinical Trial Office |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)M130-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|